Series B boost for ImCheck's gamma delta T cell therapies

ImCheck’s $53M series B will bring at least one T cell-activating antibody to the clinic, broaden immuno-oncology pipeline

With $53 million in series B funding, ImCheck plans to bring at least one of its T cell-activating antibodies into the clinic and broaden its immuno-oncology pipeline.

Pfizer Ventures and two Bpifrance funds, InnoBio 2 and Large Venture, led the round. Also joining were new investors Wellington Partners, Agent Capital, and Alexandria Venture Investments, along with existing investors

Read the full 570 word article

How to gain access

Continue reading with a
two-week free trial.